Information about Sinemet CR (Carbidopa / Levodopa ER)
Sinemet CR (Controlled Release) is a formulation of carbidopa and levodopa, designed for the treatment of Parkinson's disease. It combines two active ingredients: carbidopa, which prevents the premature conversion of levodopa into dopamine outside the brain, and levodopa, which is converted into dopamine inside the brain to help improve motor control. The "CR" in Sinemet CR stands for "controlled release," indicating that this version of the medication is designed to release the active ingredients gradually over time, offering a longer duration of symptom relief compared to regular Sinemet.
Product Highlights
- To control the symptoms of Parkinson's disease, such as tremors, rigidity, and bradykinesia (slowness of movement).
- It may also be used to treat other forms of parkinsonism caused by brain injuries or certain medications.
Key Ingredient
Key Benefits
- Levodopa restores dopamine levels in the brain, which helps improve motor symptoms such as tremors, stiffness, and bradykinesia in Parkinson’s disease.
- The controlled-release formulation provides a more consistent level of medication in the bloodstream, reducing "off" periods when symptoms worsen.
- Carbidopa helps prevent nausea and vomiting, common side effects of levodopa, by blocking the conversion of levodopa to dopamine outside the brain.
- By offering extended relief from Parkinson's symptoms, Sinemet CR helps improve mobility and daily functioning, leading to a better overall quality of life for patients.
Direction of Use
- Sinemet CR is taken by mouth in the form of extended-release tablets.
- The dosage varies depending on the severity of symptoms and the patient's response. Typical starting doses for adults may involve one or two tablets, taken 2-3 times per day. The healthcare provider will adjust the dose based on individual needs.
- It can be taken with or without food, although taking it with food can sometimes reduce nausea.
- Tablets should be swallowed whole and not crushed or chewed, as this can interfere with the controlled-release mechanism.
- Regular follow-up appointments are necessary to adjust dosing and monitor the effectiveness of the medication.
Safety Concerns
- Long-term use of Sinemet CR may lead to the development of involuntary movements (dyskinesia), particularly at higher doses.
- Although carbidopa reduces these side effects, some patients may still experience nausea, especially when starting the medication or increasing the dose.
- Patients may experience dizziness or fainting due to low blood pressure, particularly when standing up quickly.
- Older adults may experience mental health effects such as hallucinations, confusion, or agitation.
- Over time, Sinemet CR may become less effective, leading to a return of Parkinson's symptoms before the next dose is due.
- Sinemet CR can interact with other medications, including certain antidepressants, antipsychotics, and iron supplements. It is essential to notify healthcare providers of all medications being used.
Avoid Sinemet CR (Carbidopa / Levodopa ER) If
- Avoid if you have a known allergy to levodopa, carbidopa, or any other ingredients in Sinemet CR.
- Sinemet CR may increase intraocular pressure, so it should be avoided in people with narrow-angle glaucoma.
- People with severe heart conditions, such as arrhythmias, should use Sinemet CR with caution or avoid it, depending on their health status.
- Sinemet CR may exacerbate symptoms of peptic ulcers.
- There may be an increased risk of melanoma with Sinemet use, so it should be used cautiously in those with a history of skin cancer.
- Sinemet CR should not be taken with non-selective monoamine oxidase inhibitors (MAO inhibitors) due to the risk of serious side effects, including hypertensive crisis.
